MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial in Mexico

MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial in Mexico

The poor immune response elicited by trivalent influenza vaccines (TIVs) in children can be enhanced by the addition of adjuvants. This observer-blind, randomized Phase III trial assessed the immunogenicity and safety of the MF59-adjuvanted trivalent influenza vaccine FLUAD® (aTIV) and a non-adjuvan...

Full description

Bibliographic Details
Main Authors: Aurelio Cruz-Valdez, Gabriel Valdez-Zapata, Sanjay S. Patel, Flavia V. Castelli, Marcia G. Garcia, Wim T. Jansen, Ashwani Kumar Arora, Esther Heijnen
Format: Article
Language:English
Published: Taylor & Francis Group 2018-02-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
adjuvant
immunogenicity
influenza
mf59
safety
trivalent influenza vaccine
Online Access:http://dx.doi.org/10.1080/21645515.2017.1373227

Internet

http://dx.doi.org/10.1080/21645515.2017.1373227

Similar Items